Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians
© 2022 The Author(s). Published by S. Karger AG, Basel..
Assessing the risk for specific patient groups to suffer from severe courses of COVID-19 is of major importance in the current SARS-CoV-2 pandemic. This review focusses on the risk for specific patient groups with chronic respiratory conditions, such as patients with asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF), sarcoidosis, interstitial lung diseases, lung cancer, sleep apnea, tuberculosis, neuromuscular diseases, a history of pulmonary embolism, and patients with lung transplants. Evidence and recommendations are detailed in exemplary cases. While some patient groups with chronic respiratory conditions have an increased risk for severe courses of COVID-19, an increasing number of studies confirm that asthma is not a risk factor for severe COVID-19. However, other risk factors such as higher age, obesity, male gender, diabetes, cardiovascular diseases, chronic kidney or liver disease, cerebrovascular and neurological disease, and various immunodeficiencies or treatments with immunosuppressants need to be taken into account when assessing the risk for severe COVID-19 in patients with chronic respiratory diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Respiration; international review of thoracic diseases - 101(2022), 3 vom: 01., Seite 307-320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lommatzsch, Marek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000518896 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337632200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337632200 | ||
| 003 | DE-627 | ||
| 005 | 20231225234848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000518896 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337632200 | ||
| 035 | |a (NLM)35231915 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lommatzsch, Marek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Author(s). Published by S. Karger AG, Basel. | ||
| 520 | |a Assessing the risk for specific patient groups to suffer from severe courses of COVID-19 is of major importance in the current SARS-CoV-2 pandemic. This review focusses on the risk for specific patient groups with chronic respiratory conditions, such as patients with asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF), sarcoidosis, interstitial lung diseases, lung cancer, sleep apnea, tuberculosis, neuromuscular diseases, a history of pulmonary embolism, and patients with lung transplants. Evidence and recommendations are detailed in exemplary cases. While some patient groups with chronic respiratory conditions have an increased risk for severe courses of COVID-19, an increasing number of studies confirm that asthma is not a risk factor for severe COVID-19. However, other risk factors such as higher age, obesity, male gender, diabetes, cardiovascular diseases, chronic kidney or liver disease, cerebrovascular and neurological disease, and various immunodeficiencies or treatments with immunosuppressants need to be taken into account when assessing the risk for severe COVID-19 in patients with chronic respiratory diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Respiratory diseases | |
| 650 | 4 | |a Risk assessment | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Rabe, Klaus F |e verfasserin |4 aut | |
| 700 | 1 | |a Taube, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Joest, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Kreuter, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wirtz, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Blum, Torsten Gerriet |e verfasserin |4 aut | |
| 700 | 1 | |a Kolditz, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Geerdes-Fenge, Hilte |e verfasserin |4 aut | |
| 700 | 1 | |a Otto-Knapp, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Häcker, Brit |e verfasserin |4 aut | |
| 700 | 1 | |a Schaberg, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Ringshausen, Felix C |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelmeier, Claus F |e verfasserin |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Reck, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Gottlieb, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinides, Stavros |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Worth, Heinrich |e verfasserin |4 aut | |
| 700 | 1 | |a Windisch, Wolfram |e verfasserin |4 aut | |
| 700 | 1 | |a Welte, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Torsten |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiration; international review of thoracic diseases |d 1968 |g 101(2022), 3 vom: 01., Seite 307-320 |w (DE-627)NLM000076384 |x 1423-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2022 |g number:3 |g day:01 |g pages:307-320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000518896 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2022 |e 3 |b 01 |h 307-320 | ||